213,450 Shares in Bruker Corporation $BRKR Acquired by Ceredex Value Advisors LLC

Ceredex Value Advisors LLC acquired a new stake in shares of Bruker Corporation (NASDAQ:BRKR) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 213,450 shares of the medical research company’s stock, valued at approximately $12,845,000.

Several other large investors have also recently bought and sold shares of BRKR. Orbis Allan Gray Ltd raised its holdings in Bruker by 5.4% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after purchasing an additional 761,258 shares during the period. Pallas Capital Advisors LLC acquired a new position in shares of Bruker in the 2nd quarter valued at $570,746,000. State Street Corp increased its position in shares of Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after buying an additional 91,706 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares in the last quarter. Finally, Sculptor Capital LP raised its stake in Bruker by 9.0% during the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock worth $118,112,000 after buying an additional 270,000 shares during the period. Institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Stifel Nicolaus set a $50.00 price target on Bruker in a research report on Wednesday, August 5th. Leerink Partners lifted their price objective on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Wolfe Research started coverage on Bruker in a research report on Monday, June 1st. They issued a “peer perform” rating for the company. Finally, Citigroup lowered their target price on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.64.

Bruker Trading Up 2.2%

BRKR opened at $59.92 on Friday. The stock has a market capitalization of $9.13 billion, a P/E ratio of -85.60, a P/E/G ratio of 1.79 and a beta of 1.28. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $65.30. The firm’s fifty day simple moving average is $58.55 and its 200 day simple moving average is $47.39.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. During the same quarter in the prior year, the company earned $0.32 EPS. The company’s revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts anticipate that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be paid a $0.05 dividend. The ex-dividend date is Monday, September 21st. This represents a $0.20 annualized dividend and a yield of 0.3%. Bruker’s payout ratio is presently -28.57%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.